DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Sitaxentan
Sitaxentan
Endothelin System and Therapeutic Application of Endothelin Receptor
THELIN, INN-Sitaxentan Sodium
Corrigendum Doi:10.1093/Eurheartj/Ehr046
Access to New Medicines in New Zealand Compared to Australia
Modifications to the Harmonized Tariff Schedule of the United States To
Endothelin Receptor Antagonists (ERA) in Hypertension and Chronic Kidney Disease: a Rose with Many Thorns Michael N
A Novel JAK1 Mutant Breast Implant-Associated Anaplastic Large Cell Lymphoma Patient-Derived Xenograft Fostering Pre- Clinical Discoveries
A Multicentre Phase II Study of AZD1775 Plus Chemotherapy in Patients with Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer
WO 2016/044447 Al 24 March 2016 (24.03.2016) P O P C T
WO 2017/151816 Al 8 September 2017 (08.09.2017) P O P C T
New Medicine Service – List of Medicines
Thrombomodulin Is Upregulated in the Kidneys of Women with Pre‑Eclampsia Cleo C
Anatomical Classification Guidelines V2020 EPHMRA ANATOMICAL
(10) Patent No.: US 9309235 B2
Stembook 2018.Pdf
Wo 2008/116165 A2
Withdrawal of Sitaxentan in the Treatment of Pulmonary Arterial Hypertension
Endothelin ETA Receptor Blockade, by Activating ETB Receptors, Increases Vascular Permeability and Induces Exaggerated Fluid Retention S
Top View
Sitaxentan-Induced Hepatic Failure in Two Patients with Pulmonary Arterial Hypertension
THELIN, INN-Sitaxentan Sodium
THELIN (Sitaxentan Sodium) Encysive Pharmaceuticals Inc
European Pharmaceuticals Pharmaceuticals Industry Update
Supplementary File
Known Bioactive Library: Selleck Bioactive 10Mm, 3.33Mm, 1.11Mm
Anatomical Classification Guidelines V2018 EPHMRA ANATOMICAL
(12) Patent Application Publication (10) Pub. No.: US 2015/0232461 A1 Nakai Et Al
Lääkealan Turvallisuus- Ja Kehittämiskeskuksen Päätös
Final Decisions and Reasons for Decisions by Delegates of the Secretary to the Department of Health
Pulmonary Arterial Hypertension: Role of Ambrisentan
Evaluation of Carcinogenicity Studies of Medicinal Products for Human Use Authorised Via the European Centralised Procedure
Prescription Medications, Over-The-Counter Drugs, Herbs & Chemicals Associated with Tinnitus
Informed Consent Form – Group A
Pharmaceutical Compositions Comprising Prasugrel And
TBC3711, an ETA Receptor Antagonist, Reduces Neonatal Hypoxia-Induced Pulmonary Hypertension in Piglets
(12) Patent Application Publication (10) Pub. No.: US 2008/0066741 A1 Lemahieu Et Al
Oregon Drug Use Review / Pharmacy & Therapeutics Committee